ARS Pharmaceuticals, Inc. (SPRY)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Loading interactive chart…
- GuruFocus.com
ARS Pharmaceuticals Inc (SPRY) Q1 2024 Earnings: Aligns with EPS Projections Amidst Regulatory ...
Exploring ARS Pharmaceuticals' Latest Financial Performance and Strategic Milestones
- Simply Wall St.
ARS Pharmaceuticals First Quarter 2024 Earnings: US$0.11 loss per share (vs US$0.16 loss in 1Q 2023)
ARS Pharmaceuticals ( NASDAQ:SPRY ) First Quarter 2024 Results Key Financial Results Net loss: US$10.3m (loss narrowed...
- GlobeNewswire
ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results
neffy® (epinephrine nasal spray) New Drug Application (NDA) and CRL response under review by FDA with anticipated review completion by early October 2024 Response submitted for neffy Marketing Authorization Application (MAA) to EMA’s CHMP; CHMP opinion expected in the second quarter of 2024 Preparing to initiate outpatient study of neffy for urticaria (hives) in second half of 2024 $223.6 million in cash and securities as of March 31, 2024, providing an expected operating runway of at least thre
© 2024 Yahoo. All rights reserved.